Chronic treatment with the dipeptidyl peptidase-4 inhibitor BI 1356 [(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2- ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycemic control in diabetic rodent models

Journal of Pharmacology and Experimental Therapeutics

Volumn 328, Issue 2, 2009, Pages 556-563

  Thomas, Leo ^a   Tadayyon, Moh ^a   Mark, Michael ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

8 (3 AMINO 1 PIPERIDINYL) 7 (2 BUTYNYL) 3 METHYL 1 (4 METHYL 2 QUINAZOLINYLMETHYL)XANTHINE; DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; VILDAGLIPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE COMPARISON; FEMALE; GENETIC MODEL; GLYCEMIC CONTROL; LIPID DIET; MALE; MOUSE; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANIMALS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; PURINES; QUINAZOLINES; RATS; RATS, ZUCKER; TUMOR CELLS, CULTURED;

EID: 59649105751     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.143966     Document Type: Article

References (28)

1. Baggio LL and Drucker DJ (2006) Therapeutic approaches to preserve islet mass in type 2 diabetes. Annu Rev Med 57:265-281.
2. Balkau B and Eschwège E (1997) Insulin resistance: an independent risk factor for cardiovascular disease? Diabetes Obes Metab 1 (Suppl 1):S23-S31.
3. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S, Wiley C, Selvin E, Wilson R, Bass EB, et al. (2007) Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 147:386-399.
4. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153-165.
5. Eckhardt M, Langkopf E, Mark M, Tadayyon M, Thomas L, Nar H, Pfrengle W, Guth B, Lotz R, Sieger P, et al. (2007) 8-(3-(R)-Aminopiperidin-1-yl)-7- but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2, 6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes. J Med Chem 50:6450-6453.
6. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, and Perfetti R (2002) Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408.
7. Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, and Dugi KA (2007) The novel, potent, and selective DPP-4 inhibitor BI 1356 significantly lowers HbA1c after only 4 weeks of treatment in patients with type 2 diabetes, in Proceedings of the American Diabetes Association 67th Scientific Sessions; 2007 June 22-26; Chicago, IL. Abstract 0594-P, American Diabetes Association, Chicago, IL.
8. Franklin I, Gromada J, Gjinovci A, Theander S, and Wollheim CB (2005) β-Cell secretory products activate α-cell ATP-dependent potassium channels to inhibit glucagon release. Diabetes 54:1808-1815.
9. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed, Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
10. King H, Aubert RE, and Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431.
11. Luo J, Quan J, Tsai J, Hobensack CK, Sullivan C, Hector R, and Reaven GM (1998) Nongenetic mouse models of non-insulin-dependent diabetes mellitus. Metabolism 47:663-668.
12. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, and Hennekens CH (1991) A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Int Med 151:1141-1147.
13. Meier JJ and Nauck MA (2006) Incretins and the development of type 2 diabetes. Curr Diab Rep 6:194-201.
14. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, et al. (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704.
15. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, and Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36:741-744.
16. Palumbo PJ (2001) Glycemic control, mealtime glucose excursions, and diabetic complications in type 2 diabetes mellitus. Mayo Clin Proc 76:609-618.
17. Pauly RP, Rosche F, Wermann M, McIntosh CH, Pederson RA, and Demuth HU (1996) Investigation of glucose-dependent insulinotropic polypeptide-(1-42) and glucagon-like peptide-1-(7-36) degradation in vitro by dipeptidyl peptidase IV using matrix-assisted laser desorption/ionization-time of flight mass spectrometry: a novel kinetic approach. J Biol Chem 271:23222- 23229.
18. Peterson RG (2001) The Zucker diabetic fatty (ZDF) rat, in Animal Models of Diabetes: A Primer (Anders AFS and Shafrir E eds) pp 109-128, Harwood Academic Publishers, Amsterdam, The Netherlands.
19. Pratley RE and Salsali A (2007) Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 23:919-931.
20. Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, and Turner RC (1996) Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM. Diabetes 45:1524-1530.
21. Rendell M, Stephen PM, Paulsen R, Valentine JL, Rasbold K, Hestorff T, Eastberg S, and Shint DC (1985) An interspecies comparison of normal levels of glycosylated hemoglobin and glycosylated albumin. Comp Biochem Physiol B 81:819-822.
22. Taylor SI (1999) Deconstructing type 2 diabetes. Cell 97:9-12.
23. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, and Mark M (2008) (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl- quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 325:175-182.
24. Todd JF and Bloom SR (2007) Incretins and other peptides in the treatment of diabetes. Diabet Med 24:223-232.
25. Tourrel C, Bailbé D, Meile MJ, Kergoat M, and Portha B (2001) Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 50:1562-1570.
26. Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, and Hughes TE (2003) 1-[[(3-hydroxy-1-adamantyl)amino] acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46:2774-2789.
27. Villhauer EB, Brinkman JA, Naderi GB, Dunning BE, Mangold BL, Mone MD, Russell ME, Weldon SC, and Hughes TE (2002) 1-[2-[(5-Cyanopyridin-2-yl)amino] ethylamino]acetyl-2-(S)-pyrrolidinecarbonitrile: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 45:2362-2365.
28. Xu G, Stoffers DA, Habener JF, and Bonner-Weir S (1999) Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276.